SCHEMBL23977998

SCHEMBL23977998

Cc1ccnc(O[C@H](C)C(F)(F)F)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 1/20 0.46
CCR5 P51681 2/20 0.39
UHRF1 Q96T88 1/20 0.39
CCR1 P32246 1/20 0.39
CCR8 P51685 1/20 0.39
KDM4E B2RXH2 2/20 0.37
MEN1 O00255 1/20 0.37
NOS3 P29474 1/20 0.37
NOS1 P29475 1/20 0.37
NOS2 P35228 1/20 0.37
KMT2A Q03164 1/20 0.37
MAPT P10636 1/20 0.37
CRHR1 P34998 5/20 0.36
RXRA P19793 4/20 0.35
GRIN1 Q05586 4/20 0.35
GRIN2B Q13224 4/20 0.35
LRRK2 Q5S007 2/20 0.33
PIM1 P11309 1/20 0.32
PIM2 Q9P1W9 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16642358 1.00 CYP11B1 (0.46) CYP11B1CCR5UHRF1CCR1CCR8
SCHEMBL9005090 0.81 CYP11B1 (0.43) CYP11B1LRRK2PIM1PIM2
SCHEMBL20804827 0.80 UHRF1 (0.43) CCR5UHRF1CCR1CCR8KDM4E
SCHEMBL827846 0.80 UHRF1 (0.46) CCR5UHRF1CCR1CCR8KDM4E
SCHEMBL29072868 0.79 CYP11B1 (0.41) CYP11B1LRRK2PIM1PIM2
SCHEMBL30992022 0.78 UHRF1 (0.45) CCR5UHRF1CCR1CCR8KDM4E
SCHEMBL16642357 0.78 UHRF1 (0.45) CCR5UHRF1CCR1CCR8KDM4E
SCHEMBL30931754 0.78 LOXL2 (0.57) CYP11B1
SCHEMBL25209760 0.78 LOXL2 (0.57) CYP11B1
SCHEMBL25417413 0.78 CYP11B1 (0.41) CYP11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230136562-A1 SPIROUREA DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-05-04 US disclosed
US-20230136562-A1 SPIROUREA DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2023-05-04 US disclosed
WO-2021219594-A1 SPIROUREA DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230136562-A1 SPIROUREA DERIVATIVES KCNA7, PKD2, KCNN3 CYP11B1 423/4885CCR5 2517/4885UHRF1 3905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.